Aarti Drugs Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/onjhd69bjxk0vssne3dx58tt.pdf

Key Takeaways


Margin Mechanics: The Inventory Lag

Adhish Patil: "We took a conscious call but we don't want that means temporarily decline in margins is okay, but then the production should be at full scale. So that we don't lose any market share. And the natural downside of that was squeeze in the gross margin."

Demand & Pricing Environment

Harit Shah: "As far as government prices are concerned, they are almost at pre-COVID level or lower than that. And as far as demand is concerned, we expect demand to pick up in the next two or three months, February, March onwards. We expect demand to further move up. So all inventory, which were in pipeline has come down to a very realistic level now."

Specialty Chemicals: The Growth Engine


Capex Pipeline & Revenue Ambition


Segment Dynamics

SegmentTrendCommentary
API▲ 9% YoY revenue growthDriven by increased share of chronic and acute therapies.
Formulation▼ 9% YoY declineDecline is technical: product manufactured for a Latin American tender was shipped to the subsidiary as an internal sale. Revenue will be recognized in the March quarter when sold to the final authorities in that country.
Specialty Chemicals▲ Growth driverExpected to grow at a higher pace than API, supported by brownfield expansion commitments and a greenfield pipeline.
Adhish Patil: "The products in which we are there, because the fact that our capacities are as big as Chinese, if not bigger than them in many of the cases, in the top 15 products which we manufacture, that is the reason why we are able to market our products at par with China."

Regulatory & Market Access

Adhish Patil: "In some of the multinationals, who are procuring APIs in their formulation plant for both US as well as European market, they refrain procuring from us because their product is going to both the markets, and we are approved only for Europe and not for US. So that is challenging sometimes. ... if we clear US FDA, then even the Europe market will open up fully for us from that facility."

Guidance & Commitments

CommitmentSpecificsTimeline
Gross margin improvementLow-cost inventory flows through, improving margins provided prices do not fall furtherQ4 FY23 onwards
Volume recoveryVolume off-take returns to growth trajectoryWithin 2–3 months (Feb–Mar 2023)
Specialty Chemicals revenue doublingDouble revenue from existing brownfield facilities onlyNext 12 months
Specialty Chemicals capacity scale-upEquipment arrives, production scales immediatelyApril 2023
Tarapur greenfield operationalConstruction complete, scale-up batches beginEnd of Q1 FY24 (June 2023)
All expansions completeBrownfield + greenfield + antidiabeticEnd of FY24 (worst case)
Total revenue potential~₹4,500 cr including new capex and existing utilizationAfter all expansions complete
EBITDA margin target~15–16% at higher utilization; ~18% with higher spec chem and export formulation exposureAfter all expansions complete
Specialty Chemicals revenue mix20–25% of standalone revenueAfter 2–3 years
Formulation revenue recognitionLatin American tender revenue bookedMarch quarter (Q4 FY23)

Key Metrics

MetricQ3 FY23
Standalone revenue₹614.4 cr, +6% YoY from ₹579.9 cr
Consolidated revenue contribution (standalone)92% tentatively
Domestic revenue growth+8% YoY
Export revenue growth+2% YoY
API segment revenue growth+9% YoY
Formulation segment revenue₹49.9 cr, 8% of total revenue
Formulation segment revenue growth-9% YoY
Specialty intermediate and others revenue growth (9M FY23)+15% YoY
Gross margin34% (per an analyst's math), flat YoY
Inventory loss₹6 cr, contributing ~1% to gross margin squeeze
Total capex (9M FY23)₹115 cr
Total capex guidance (FY23)₹200 cr to ₹250 cr
Net debt-to-equity0.53x as of December 31, 2022
API therapeutic mix: antibiotic45% of API sales
API therapeutic mix: antidiabetic16% of API sales
API therapeutic mix: antiprotozoal16% of API sales
API therapeutic mix: anti-inflammatory12% of API sales
API therapeutic mix: antifungal8% of API sales
Domestic volume growth+2% to +3% YoY, flattish marginal
Export volume growthSlight de-growth YoY
Specialty chemicals revenue share4% to 5% of standalone revenue
Specialty chemicals and intermediates revenue target20% to 25% of standalone revenue in 2–3 years
Revenue potential post-expansions~₹4,500 cr including brownfield, greenfield, and antidiabetic facility
EBITDA margin target (current business, higher utilization)15% to 16%
EBITDA margin target (post all expansions)Towards 18%
Raw material inventory days~100 days at start of December quarter